Jan Hendrik Muller | Oncology and Pathology | Best Researcher Award

Published on by Shen Awards

Mr. Jan Hendrik Muller | Oncology and Pathology | Best Researcher Award

University Clinic Hamburg Eppendorf | Germany

Mr. Jan Hendrik Müller is an accomplished researcher in molecular life sciences with a specialization in cancer proteomics and translational medicine. Currently pursuing his Ph.D. at the Institute of Pathology, University Medical Center Hamburg-Eppendorf, he has established himself as a promising scientist with expertise in cutting-edge proteomic technologies such as LC-MS/MS and mass spectrometry. His academic career reflects a strong foundation in molecular biology, proteomics, and life science research, supported by rigorous training at leading German institutions including the University of Hamburg and Leibniz University Hannover. Jan’s research focuses on understanding cancer biology at the proteomic level, with the aim of identifying novel biomarkers and therapeutic targets. Alongside his academic journey, he has contributed as a research assistant in internationally recognized groups, gaining practical experience in experimental oncology, T-cell research, and collaborative scientific projects. His involvement in both laboratory research and medical volunteer work highlights his dedication to bridging science and societal benefit. Beyond technical expertise, Jan brings leadership, adaptability, and teamwork to his professional profile, making him a well-rounded candidate for recognition. His ability to integrate scientific curiosity with practical applications positions him as a researcher with significant potential to impact both academia and medical science in the future.

Professional Profile

Education

Mr. Jan Hendrik Müller has pursued a progressive and rigorous academic journey in the field of life sciences, developing expertise in molecular biology, proteomics, and translational medicine. He began his higher education at Leibniz University Hannover, where he earned his Bachelor of Science (B.Sc.) in Life Science. During his undergraduate years, Jan developed proficiency in molecular biology techniques including PCR, protein isolation, and confocal microscopy. His bachelor’s thesis, titled “The effects of dextran sodium sulfate on the barrier function of epithelial cells,” allowed him to gain experience in cell culture and epithelial biology. Following this, Jan pursued his Master of Science (M.Sc.) in Molecular Life Science at the University of Hamburg, completing his degree with excellent academic standing. His master’s studies were research-oriented, involving advanced training in proteomics under the guidance of Prof. Dr. Hartmut Schlüter. His projects included mass spectrometry analysis of prostate cancer tissue, contributing to translational cancer research. Building upon this foundation, Jan is currently enrolled in a Doctor of Philosophy (Ph.D.) program at the University Medical Center Hamburg-Eppendorf, focusing on cancer proteomics and drug response profiling. His educational background demonstrates consistent excellence, hands-on laboratory expertise, and a strong commitment to advancing biomedical research.

Professional Experience

Mr. Jan Hendrik Müller’s professional experience demonstrates a balanced combination of academic research, laboratory training, and clinical exposure. Early in his career, he trained as a paramedic and served in hospital settings, gaining valuable insights into patient care and surgical assistance, particularly in orthopedic surgeries. These experiences nurtured his sense of responsibility and motivated his transition from clinical service to biomedical research. During his academic career, he worked as a Research Assistant in the laboratory of Prof. Dr. Hartmut Schlüter at the University Medical Center Hamburg-Eppendorf. There, he specialized in proteomic analysis of prostate cancer tissue using LC-MS/MS, gaining expertise in mass spectrometry, sample preparation, and proteomic pathway analysis. He also contributed to collaborative projects on T-cell immunotherapy, including viral transduction and functional assays for CAR-T-cell research. In addition, Jan has managed laboratory responsibilities such as cryobank administration and patient sample handling, demonstrating both technical and organizational skills. His professional development is also marked by active teamwork in multidisciplinary projects and community service in hospital environments. These diverse experiences highlight his ability to integrate clinical relevance with scientific discovery, making him a well-rounded researcher equipped for impactful contributions to cancer biology and translational medicine.

Research Interests

Mr. Jan Hendrik Müller’s research interests lie at the intersection of molecular biology, proteomics, and translational oncology. His primary focus is the proteomic profiling of cancer tissues, particularly prostate cancer, using advanced techniques such as liquid chromatography coupled with mass spectrometry (LC-MS/MS). Through this approach, he seeks to unravel the molecular mechanisms underlying cancer progression and drug responses, with the goal of identifying novel therapeutic targets and biomarkers for early diagnosis. In addition to cancer proteomics, Jan is also interested in immunotherapy research, having gained experience in CAR-T-cell biology, viral transduction methods, and T-cell functional assays. His broader research goals include integrating proteomic data with systems biology to provide holistic insights into cellular pathways affected by novel drug treatments. Beyond oncology, Jan shows interest in the applications of molecular life sciences in personalized medicine, aiming to develop strategies that bridge fundamental research with clinical application. His interdisciplinary approach reflects his commitment to collaborative science, combining expertise in molecular biology, analytical chemistry, and clinical medicine. Ultimately, his research interests highlight a forward-looking vision to contribute meaningfully to cancer research, drug development, and precision medicine.

Research Skills

Over the course of his academic and professional journey, Mr. Jan Hendrik Müller has developed a broad and advanced skill set in experimental life sciences and proteomics. His expertise includes molecular biology techniques such as PCR, protein production, blotting, and electrophoresis, alongside advanced cell culture methods, including the maintenance of various cell lines and epithelial barrier function analysis. He is proficient in high-level proteomic methodologies, particularly LC-MS/MS and mass spectrometry-based proteome analysis, enabling him to study complex biological samples with precision. In the field of immunology, he has acquired skills in isolation, expansion, and viral transduction of T-cells, as well as functional CAR-T-cell assays. Jan also has experience in fluorescence-activated cell sorting (FACS), confocal microscopy, and proteomic pathway analysis, demonstrating technical versatility. Beyond laboratory skills, he is proficient in bioinformatics tools such as ImageJ, Matlab, and LaTeX for data visualization and documentation. His certifications include Good Manufacturing Practices (GMP), further enhancing his competency in clinical-grade research. In addition, Jan has proven skills in teamwork, problem-solving, and communication, strengthened by his volunteer work in medical and community settings. Together, his research skills position him as a highly capable scientist ready to contribute to complex biomedical projects.

Awards and Honors

While still in the early stages of his academic career, Mr. Jan Hendrik Müller has already received recognition for his academic and professional excellence. During his Master of Science program at the University of Hamburg, he achieved excellent grades, including a distinction in several advanced courses. His bachelor’s and master’s theses received commendation for their originality and scientific rigor, particularly in the field of proteomics and epithelial biology. Jan has also been awarded a certificate in Good Manufacturing Practices (GMP), reflecting his adherence to the highest standards of laboratory and clinical research practices. In addition to formal recognition, his contribution to research projects under internationally respected mentors such as Prof. Dr. Hartmut Schlüter has allowed him to build a reputation as a promising scientist in proteomics research. His community service in hospital environments and volunteer platforms further demonstrate his commitment to societal well-being. While he has yet to receive large-scale international honors, his strong research foundation, combined with his growing publication record and academic contributions, suggests a career trajectory that will lead to greater recognition in the global scientific community in the near future.

Publication TOp Notes

  • High-level STING expression in tumour and inflammatory cells is linked to microsatellite instability and favourable tumour parameters in a cohort of over 1,900 colorectal cancer patients — 2025

  • A Tc1- and Th1-T-lymphocyte-rich tumor microenvironment is a hallmark of MSI colorectal cancer — 2025

  • Prognostic Impact and Spatial Interplay of Immune Cells in Urothelial Cancer — 2024

  • Loss of TROP2 and epithelial cell adhesion molecule expression is linked to grade progression in pTa but unrelated to disease outcome in pT2-4 urothelial bladder carcinomas — 2024

  • Automated Prognosis Marker Assessment in Breast Cancers Using BLEACH&STAIN Multiplexed Immunohistochemistry — 2023

Conclusion

In conclusion, Mr. Jan Hendrik Müller exemplifies the qualities of a dedicated and innovative young researcher in the field of molecular life sciences and cancer proteomics. His academic excellence, demonstrated through his bachelor’s, master’s, and ongoing Ph.D. studies, reflects his consistent pursuit of scientific knowledge and translational medicine. His professional experiences, ranging from hospital assistance to advanced cancer proteomic research, reveal a well-rounded individual capable of integrating clinical insights with laboratory discoveries. With expertise in proteomics, immunotherapy, and molecular biology, Jan has built a diverse skill set that positions him as a valuable contributor to biomedical science. His community involvement, volunteer medical service, and collaborative research engagements highlight his leadership qualities and social responsibility. While there is room for further recognition through expanded publications and global collaborations, his trajectory demonstrates great promise. Jan is not only contributing to cancer research but is also laying the foundation for impactful work in personalized medicine and future healthcare innovation. These achievements, combined with his dedication, make him a deserving candidate for recognition and a strong contender for future leadership in biomedical research.

Hossein Aminianfar | Anatomic Pathology | Best Researcher Award

Published on by Shen Awards

Assist. Prof. Dr. Hossein Aminianfar | Anatomic Pathology | Best Researcher Award

Academic Faculty from University of Tehran, Iran

Dr. Hossein Aminianfar is a dedicated academic and veterinary anatomic pathologist with a strong reputation in translational research, toxicologic pathology, and regenerative medicine. With a combination of scholarly excellence and applied diagnostic expertise, he brings a multidimensional perspective to the field of veterinary science. Currently serving as an Assistant Professor at the University of Tehran’s Faculty of Veterinary Medicine, he is also the founder and CEO of ArenaPath, a specialized service for comparative pathology in Tehran. His extensive publication record in internationally indexed journals, covering a range of topics from stem cell therapies to vaccine safety and biomaterials, underscores his commitment to impactful, cross-disciplinary research. Dr. Aminianfar is recognized for his diagnostic proficiency in veterinary pathology, particularly in equine, ruminant, and forensic cases. His affiliations with leading professional societies, including the American Society of Toxicology Pathology, reinforce his active engagement with the global scientific community. He has also earned multiple certifications and contributed to high-profile research studies in both academic and clinical contexts. His passion for advancing veterinary diagnostics and bridging the gap between laboratory findings and clinical application make him a significant contributor to his field and a strong contender for prestigious research awards.

Professional Profile

Education

Dr. Hossein Aminianfar holds an impressive academic background rooted in veterinary medicine and pathology. He earned his Doctor of Veterinary Medicine (DVM) degree in 2012 from the University of Tehran, Iran, laying the foundation for his specialized career. Continuing his academic pursuit, he completed his Doctorate in Veterinary Anatomic Pathology (DVSc) from the same institution in 2017. His DVM dissertation, titled “Preparation and assessment of histological, biochemical, and biomechanical properties of extracellular matrix produced from the host tissue response against subcutaneously-implanted dextran hydrogel in rats,” was recognized internationally and presented at the 2nd Joint European Congress of the ESVP, ESTP, and ECVP in Berlin. His doctoral thesis, “Osteogenic differentiation of mesenchymal stem cells by osteoblast-imprinted substrate,” demonstrated his expertise in regenerative medicine and cellular pathology. This academic journey highlights his deep engagement with experimental research and translational science. Dr. Aminianfar’s formal education reflects not only his technical skill but also his ability to address complex scientific questions, paving the way for innovative applications in both veterinary and human biomedical sciences. His strong educational foundation has been instrumental in shaping his career in academia and in the development of advanced diagnostic and therapeutic techniques.

Professional Experience

Dr. Hossein Aminianfar brings a wealth of experience in both academic and professional domains of veterinary pathology. He currently serves as an Assistant Professor in the Department of Pathology at the Faculty of Veterinary Medicine, University of Tehran, a role he has held since 2022. His responsibilities include teaching, supervising student research, and leading cutting-edge investigations in toxicologic and comparative pathology. In 2021, he founded ArenaPath, a comparative pathology service based in Tehran, where he functions as both Founder and CEO. This venture provides diagnostic services and fosters collaboration between research institutions and veterinary clinics. In addition to academia and entrepreneurship, Dr. Aminianfar has substantial experience in veterinary diagnostics, particularly in diagnosing ruminant abortions, placenta pathology, equine disorders, and forensic pathology. His role on the pathology committee of the Iranian Veterinary Society and his membership in the Research Council of the Urology Research Center at Tehran University of Medical Sciences underscore his interdisciplinary influence. He also holds memberships in several respected scientific organizations, such as the American Society of Toxicology Pathology and the Institute of Biomedical Research. Collectively, his professional trajectory reflects a blend of research innovation, practical diagnostic application, and educational leadership in the field.

Research Interests

Dr. Aminianfar’s research interests lie at the intersection of veterinary pathology, regenerative medicine, and translational biomedical sciences. He is particularly focused on toxicologic pathology and the pre-clinical evaluation of pharmaceuticals in animal models. His work in this area contributes to the safety and efficacy testing of novel drug compounds, bridging laboratory science with clinical applications. Regenerative medicine also forms a core part of his scientific interests, particularly in osteogenesis, cartilage repair, and wound healing using advanced materials such as nanofibers and bioceramic scaffolds. Additionally, he has a strong interest in the osteogenic differentiation of stem cells, 3D-bioprinting, and the role of extracellular matrices in tissue regeneration. His research has also extended into COVID-19 vaccine safety in non-human primates, indicating his capability to contribute to both human and animal health sciences. These diverse interests align with global scientific priorities and enhance his ability to collaborate across disciplines. His work frequently merges material science, biotechnology, and cellular biology, making him an asset in cross-disciplinary research teams. Dr. Aminianfar’s vision is to continue contributing toward the development of safe and effective biomedical products, while advancing diagnostic methods that serve both veterinary and medical communities.

Research Skills

Dr. Hossein Aminianfar possesses a versatile and robust set of research skills that underpin his scientific contributions across various domains. His core technical competencies include histopathological evaluation, immunohistochemistry, and molecular diagnostics, which he uses to investigate complex pathological conditions in animals. He is adept in stem cell culturing, scaffold fabrication, and in vitro/in vivo models, particularly those related to bone and cartilage regeneration. His expertise in designing and conducting animal model studies for drug safety and potency assessments is highly valued in pre-clinical research environments. Dr. Aminianfar also demonstrates significant capability in scientific writing, data analysis, and interdisciplinary collaboration, as reflected in his co-authorship of more than 20 peer-reviewed journal articles. He is trained in laboratory animal handling and ethical research protocols, having completed certified courses in toxicologic pathology and animal experimentation. His diagnostic acumen in veterinary pathology, especially concerning ruminant abortion and equine diseases, complements his laboratory-based skills. These competencies are strengthened by his ability to translate complex experimental outcomes into practical insights and scientific innovations. Overall, Dr. Aminianfar’s research skills position him as a knowledgeable and dependable researcher capable of leading studies with both scientific rigor and clinical relevance.

Awards and Honors

Dr. Aminianfar’s career reflects a steady progression of achievements, certifications, and acknowledgments that affirm his credibility in the scientific and veterinary communities. Though he has not listed traditional awards, he has obtained multiple professional certifications from prestigious organizations. These include a certification in “Optimizing Toxicologic Pathology Data” from the Society of Toxicologic Pathology and participation in specialized courses offered by the Davis-Thompson Foundation, such as toxicologic pathology and pathology of abortion in various animals. He also completed certified training on the principles of working with laboratory animals, administered by the National Institute for Medical Research Development under Iran’s Ministry of Health and Medical Education. His academic presentations, including his dissertation showcased at the European Congress in Berlin, serve as further testimony to his scholarly recognition. Additionally, his role on the pathology committee of the Iranian Veterinary Society and his membership in multiple scientific councils demonstrate trust and leadership within his professional networks. These honors, combined with his certification track record and research-based recognitions, confirm Dr. Aminianfar’s position as an active and credible member of both national and international research communities.

Conclusion

In conclusion, Dr. Hossein Aminianfar stands out as a dynamic and impactful researcher in the field of veterinary anatomic pathology. His multidisciplinary expertise, encompassing regenerative medicine, toxicologic pathology, and translational science, uniquely positions him to contribute to both academic and clinical advancements. As an academic, entrepreneur, and diagnostician, he brings a rare combination of skills that bridge the gap between theory and practice. His extensive publication record, professional certifications, and leadership roles in various scientific bodies reinforce his status as a dedicated and accomplished researcher. While his career could further benefit from increased international collaborations, patent outputs, and grant leadership, the depth and quality of his current contributions are undeniably strong. Dr. Aminianfar’s research not only supports the development of innovative therapeutic solutions but also enhances diagnostic practices in veterinary medicine. His forward-looking approach, commitment to scientific integrity, and dedication to applied research make him a highly deserving candidate for the Best Researcher Award. As he continues to explore new scientific frontiers and mentor emerging researchers, Dr. Aminianfar is poised to make even greater contributions to global science and healthcare.

Publication Top Notes

1. A Report of Aflatoxicosis in Hand-fed Ewe Lambs Exhibiting Icterus After Hepatic Failure and Hemoglobinuria

Authors: Aminianfar, H.; Samiee, N.; Sharifzadeh, A.; Lalehpoor, M.; Safavi, S.F.; Hooyeh, M.M.
Year: 2024

2. Evaluating Osteogenic Potential of a 3D-Printed Bioceramic-Based Scaffold for Critical-sized Defect Treatment: An In Vivo and In Vitro Investigation

Authors: Safiaghdam, H.; Baniameri, S.; Aminianfar, H.; Mohajeri, S.F.; Dehghan, M.M.; Tayebi, L.; Nokhbatolfoghahaei, H.; Khojasteh, A.
Year: 2024

3. Targeted Delivery of Doxorubicin by SP5-52 Peptide Conjugated Exosome Nanoparticles into Lung Tumor: An In Vitro and In Vivo Study

Authors: Ayda; Shirangi, A.; Asadi, M.; Farokhi, M.; Gholami, M.; Aminianfar, H.; Atyabi, F.; Rassoul Dinarvand
Year: 2023

4. Characterization of Stability, Safety and Immunogenicity of the mRNA Lipid Nanoparticle Vaccine Iribovax® Against COVID-19 in Nonhuman Primates

Authors: Zamani, P.; Mashreghi, M.; Rezazade Bazaz, M.; Zargari, S.; Alizadeh, F.; Dorrigiv, M.; Abdoli, A.; Aminianfar, H.; Hatamipour, M.; Zarqi, J. et al.
Year: 2023

5. 3D‐Printed MgO Nanoparticle Loaded Polycaprolactone β‐Tricalcium Phosphate Composite Scaffold for Bone Tissue Engineering Applications: In‐Vitro and In‐Vivo Evaluation

Authors: Safiaghdam, H.; Nokhbatolfoghahaei, H.; Farzad-Mohajeri, S.; Dehghan, M.M.; Farajpour, H.; Aminianfar, H.; Bakhtiari, Z.; Jabbari Fakhr, M.; Hosseinzadeh, S.; Khojasteh, A.
Year: 2023

6. Comparison of Engineered Cartilage Based on BMSCs and Chondrocytes Seeded on PVA‐PPU Scaffold in a Sheep Model

Authors: Taghizadehjahed, M.; Sepahdar, A.; Rabiee, N.; Nazbar, A.; Farzad-Mohajeri, S.; Dehghan, M.M.; Shokrgozar, M.A.; Majidi, M.; Mardjanmehr, S.H.; Aminianfar, H. et al.
Year: 2022

7. Novel Therapeutic Approach to Slow Down the Inflammatory Cascade in Acute/Subacute Spinal Cord Injury

Authors: Hashemizadeh, S.; Hosseindoost, S.; Omidi, A.; Aminianfar, H.; Ebrahimi-Barough, S.; Ai, J.; Arjmand, B.; Hadjighassem, M.
Year: 2022

8. An Incidence of Aflatoxicosis in Hand-fed Ewe Lambs Exhibiting Icterus Subsequent to Hepatic Failure and Hemoglobinuria

Authors: Hooyeh, M.M.; Aminianfar, H.; Sharifzadeh, A.; Lalehpoor, M.; Samiee, N.
Year: 2022

9. An Integrated Microfluidic Device for Stem Cell Differentiation Based on Cell-imprinted Substrate Designed for Cartilage Regeneration in a Rabbit Model

Authors: Kashani, S.Y.; Moraveji, M.K.; Taghipoor, M.; Kowsari-Esfahan, R.; Hosseini, A.A.; Montazeri, L.; Dehghan, M.M.; Gholami, H.; Farzad-Mohajeri, S.; Mehrjoo, M. et al.
Year: 2021